United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in naltrexone hydrochloride is a pure opioid antagonist. it does not lead to physical or psychological dependence. tolerance to the opioid antagonist effect is not known to occur.

United States - English - NLM (National Library of Medicine)

h.j. harkins company inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: patients receiving opioid analgesics. patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). patients in acute opioid withdrawal (see warnings). any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - methylnaltrexone bromide 12mg (12mg in 0.6ml) - solution for injection - 12 mg/0.6ml - active: methylnaltrexone bromide 12mg (12mg in 0.6ml) excipient: glycine hydrochloric acid sodium calcium edetate sodium chloride sodium hydroxide water for injection - relistor is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care when response to laxative therapy has not been sufficient.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - mesna - solution for injection/infusion - 100 milligram(s)/millilitre - detoxifying agents for antineoplastic treatment; mesna

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - mesna - solution for infusion or injection - mesna 100 mg/ml - all other therapeutic products

United States - English - NLM (National Library of Medicine)

complete pharmacy and medical solutions - naltrexone (unii: 5s6w795cqm) (naltrexone - unii:5s6w795cqm), triamcinolone (unii: 1zk20vi6ty) (triamcinolone - unii:1zk20vi6ty) - treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. naltrexone tablets were initially approved by the fda in 1985 for the treatment of abuse and addiction of opioids. naltrexone in oral and extended release injection forms have been approved by the fda for the treatment and abuse of alcohol. naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. naltrexone is contraindicated in: - patients receiving opioid analgesics (see precautions). - patients with current physiologic opioid dependence (see warnings). - patients in acute opiate withdrawal (see warnings). - any individual who has failed the naloxone challenge test or has a positive urine screen for opioids.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - cyclophosphamide - powder for solution for injection - 1000 milligram(s) - nitrogen mustard analogues; cyclophosphamide

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - cyclophosphamide - powder for solution for injection - 500 milligram(s) - nitrogen mustard analogues; cyclophosphamide

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - cyclophosphamide monohydrate - powder for solution for injection - cyclophosphamide monohydrate 500 mg - antineoplastic agents